source
- Pfizer partners with China's Innovent Biologics on $10 billion cancer drug collaborationPfizer announced a major partnership with Chinese biotech Innovent Biologics, valued at over $10 billion, to develop cancer therapies. The agreement covers up to 12 antibody-based candidates, incl…
- Merck touts promising ADC sacituzumab tirumotecan as potential cornerstone therapy at ASCOMerck highlighted a new antibody-drug conjugate, sacituzumab tirumotecan (sac-TMT), licensed from Chinese biotech Kelun-Biotech, at the ASCO meeting. The company said early clinical data have give…